{"id":10648,"date":"2023-02-27T10:08:25","date_gmt":"2023-02-27T09:08:25","guid":{"rendered":"https:\/\/cube-labs.com\/?p=10648"},"modified":"2023-02-27T10:08:25","modified_gmt":"2023-02-27T09:08:25","slug":"cartilago-receives-notice-of-allowance-in-the-usa-for-its-regenerative-medicine-patent-application-for-osteoarthritis-and-dermal-indications","status":"publish","type":"post","link":"https:\/\/pazlab.cube-labs.com\/it\/news\/cartilago-receives-notice-of-allowance-in-the-usa-for-its-regenerative-medicine-patent-application-for-osteoarthritis-and-dermal-indications\/","title":{"rendered":"Cartilago receives \u201cNotice of allowance\u201d in the USA for its regenerative medicine patent application for osteoarthritis and dermal indications"},"content":{"rendered":"

27 February 2023<\/em><\/strong>
ROME, Italy<\/em><\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

Cartilago SRL (\u201dCartilago<\/a>\u201d), a clinical stage regenerative medicine company founded by Cube Labs,<\/a> announced today that the United States Patent & Trademark Office (\u201dUSPTO\u201d) has issued a \u201cNotice of Allowance\u201d, which means that it intends to grant Cartilago\u2019s patent application. Once formally granted, the US patent will provide Cartilago\u2019s regenerative dermal and chondroprotective molecules for combatting osteoarthritis and related pathologies with broad protection in a key market, significantly strengthening the company\u2019s patent portfolio.<\/p>\n\n\n\n

The United States Patent & Trademark Office (USPTO) has communicated its intention to grant Cartilago\u2019s Patent Application No. 17\/277,876. The patent belongs to Cartilago\u2019s second patent family and covers Cartilago\u2019s technology for therapies in development for osteoarthritis and dermal indications, which stimulate the production of new cartilage tissue, as well as the generation of extracellular matrix and collagen, and the endogenous production of hyaluronic acid.<\/p>\n\n\n\n

The patent will be granted once the issue fee is paid by Cartilago and necessary formalities have been completed by the USPTO. The patent term will then extend to September 2039, and potentially longer if adjustment is made for any delays in the processing at the patent office.<\/p>\n\n\n\n

Related patent applications are pending in Europe, China and Japan.<\/p>\n\n\n\n

\u201dThis patent provides very important protection for our disease-modifying technologies for osteoarthritis and dermal regeneration,\u201d<\/em> stated Dr. Filippo Surace, Founder and CEO of Cube Labs<\/strong>. \u201cThis is a key market representing over 50% of the global pharmaceutical market and is important territory for innovative therapies such as ours. USPTO\u2019s decision to grant this patent will substantially strengthen our market position.\u201d<\/em><\/p>\n\n\n\n

Cartilago\u2019s lead pipeline technology is a transformative, disease-modifying treatment for osteoarthritis. In addition, the company announced in November 2022 clinical study results confirming the efficacy of Regen Longevity in reducing periocular wrinkles.<\/p>\n\n\n\n

About Cartilago: Advanced Solutions in Regenerative Medicine<\/strong><\/p>\n\n\n\n

Cartilago<\/a> is a clinical stage regenerative medicine company that develops disease-modifying, chondro- and dermo-protective technologies for combatting osteoarthritis and related pathologies, and anti-ageing solutions for skincare and wound care. Cartilago\u2019s regenerative technologies are centered upon molecules that display extraordinary potency in stimulating the production of new cartilage tissue, as well as the generation of extracellular matrix and collagen, and the endogenous production of hyaluronic acid.<\/p>\n\n\n\n

About Cube Labs<\/strong><\/p>\n\n\n\n

Cube Labs is a venture builder in the healthcare technology space in Italy, designed to address the gap between the excellent local academic science and the commercially promising life sciences market. Cube Labs builds new companies from promising R&D and enables innovation in order to transform pioneering science into healthcare solutions. Through its international network, Cube Labs works together with communities interested in innovation to transform outcomes for patients and accelerate the world\u2019s transition to optimal health.<\/p>\n\n\n\n

<\/p>\n\n\n\n

Cube Labs
Global Media Contact<\/strong>
Isil Guney
Tel: +90 5325027243
E-mail: i.guney@cube-labs.com<\/p>\n\n\n\n

SEC and Partners
Ufficio Stampa Italia di Cube Labs<\/strong>
Matteo Steinbach
Cell. +393461063989
E-mail: matteo.steinbach@secnewgate.it<\/p>\n\n\n\n

Federico Ziglioli
Cell. +393331225959
E-mail: federico.ziglioli@secnewgate.it<\/p>","protected":false},"excerpt":{"rendered":"

27 February 2023ROME, Italy Cartilago SRL (\u201dCartilago\u201d), a clinical stage regenerative medicine company founded by Cube Labs, announced today that the United States Patent & Trademark Office (\u201dUSPTO\u201d) has issued a \u201cNotice of Allowance\u201d, which means that it intends to grant Cartilago\u2019s patent application. Once formally granted, the US patent will provide Cartilago\u2019s regenerative dermal […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"none","_seopress_titles_title":"Cartilago receives \u201cNotice of allowance\u201d in the USA","_seopress_titles_desc":"Cartilago announced today that the United States Patent & Trademark Office (\u201dUSPTO\u201d) has issued a \u201cNotice of Allowance\u201d in the USA","_seopress_robots_index":"","footnotes":""},"categories":[48,49,50,56,60],"tags":[72,66,62,67,63,64,68,74,58],"class_list":{"0":"post-10648","1":"post","2":"type-post","3":"status-publish","4":"format-standard","6":"category-news","7":"category-tech","8":"category-financial","9":"category-business","10":"category-industry","11":"tag-borsa-italiana","12":"tag-cartilago","13":"tag-ceo","14":"tag-cube-labs","15":"tag-cube-labs-venture-studio","16":"tag-filippo-surace","17":"tag-filippo-surace-ceo","18":"tag-quotation","19":"tag-venture"},"acf":[],"_links":{"self":[{"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/posts\/10648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/comments?post=10648"}],"version-history":[{"count":0,"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/posts\/10648\/revisions"}],"wp:attachment":[{"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/media?parent=10648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/categories?post=10648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pazlab.cube-labs.com\/it\/wp-json\/wp\/v2\/tags?post=10648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}